Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
2
Neutral
8
Bullish
4
Bearish
11
Neutral
8
Bullish
27
Bearish
9
Neutral
0
Bullish
23
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q4 FY26
Investor Presentation
Q2 FY26
Mahamaya Lifesciences Ltd (MAHALIFE) is currently trading at 176.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Mahamaya Lifesciences Limited is an integrated agrochemical company that manufactures, formulates, and markets crop protection and biological solutions across domestic and export markets, operating a modern Dahej manufacturing and R&D facility and selling a portfolio exceeding fifty products including branded formulations and bulk supplies to Indian firms and multinational customers. FY26 consolidated revenue grew 24.5% year-on-year to Rs. 32,887.30 lakhs, with EBITDA increasing 32.1% to Rs. 3,425.88 lakhs and EBITDA margin expansion of 60 basis points to 10.42%, reflecting improved operational efficiencies and stronger top-line momentum despite certain non-operating accounting and listing-related charges totaling around Rs. 411 lakhs. Management highlighted durable underlying business resilience, reporting healthy H2 FY26 performance with improving margins and a deliberate shift toward sustainable biological crop-care products, signalling strategic reallocation of portfolio emphasis toward Neem-based bio-insecticides, bio-fungicides and seaweed-extract biostimulants to capture sustainability-driven demand growth in India and exports. The company completed an IPO in November 2025 raising approximately Rs. 70.44 crores and converted to a public company in 2024; proceeds and access to capital markets underpin potential scaling of bio-product manufacturing, regulatory registrations and broader geographic distribution to deepen presence across states and target export geographies.
Over the past 52 weeks, Mahamaya Lifesciences Ltd has traded between a low of ₹111.00 and a high of ₹205.05. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Mahamaya Lifesciences Ltd has a market capitalization of approximately 400.23. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Mahamaya Lifesciences Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 24.23 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 400.23 Cr, Mahamaya Lifesciences Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Mahamaya Lifesciences Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Mahamaya Lifesciences Ltd is 24.23. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Mahamaya Lifesciences Limited is an integrated agrochemical company that manufactures, formulates, and markets crop protection and biological solutions across domestic and export markets, operating a modern Dahej manufacturing and R&D facility and selling a portfolio exceeding fifty products including branded formulations and bulk supplies to Indian firms and multinational customers.
FY26 consolidated revenue grew 24.5% year-on-year to Rs. 32,887.30 lakhs, with EBITDA increasing 32.1% to Rs. 3,425.88 lakhs and EBITDA margin expansion of 60 basis points to 10.42%, reflecting improved operational efficiencies and stronger top-line momentum despite certain non-operating accounting and listing-related charges totaling around Rs. 411 lakhs.
Management highlighted durable underlying business resilience, reporting healthy H2 FY26 performance with improving margins and a deliberate shift toward sustainable biological crop-care products, signalling strategic reallocation of portfolio emphasis toward Neem-based bio-insecticides, bio-fungicides and seaweed-extract biostimulants to capture sustainability-driven demand growth in India and exports.
The company completed an IPO in November 2025 raising approximately Rs. 70.44 crores and converted to a public company in 2024; proceeds and access to capital markets underpin potential scaling of bio-product manufacturing, regulatory registrations and broader geographic distribution to deepen presence across states and target export geographies.
Fertilizers & Agrochemicals
Pesticides & Agrochemicals
400 Cr
Low Risk
24.2
18.4
0.4
3.3
205.05
111.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
144.80 | 594 Cr | -7.73 | 0.78 | 0.00 | -10.03 | -1.57 | -3.90 | ||
13.91 | 525 Cr | 17.73 | 0.77 | 0.68 | 1.15 | 5.22 | 1.76 | ||
298.75 | 501 Cr | 25.50 | 0.83 | 0.16 | 2.03 | 4.36 | 2.40 | ||
183.24 | 463 Cr | 13.00 | 1.20 | 0.00 | 8.23 | 13.07 | 8.21 | ||
176.80 | 400 Cr | 24.23 | 3.28 | 0.00 | 13.55 | 15.05 | 5.32 | ||
61.00 | 370 Cr | 9.59 | 0.81 | 0.00 | 8.71 | 10.76 | 4.68 | ||
5.06 | 217 Cr | 35.81 | 2.51 | 0.00 | 5.92 | 7.26 | 5.27 | ||
| Median: 7 Co. | — | 144.80 | 463 Cr | 17.73 | 0.83 | 0.00 | 5.92 | 7.26 | 4.68 |
